肺癌患者血清内皮抑素的表达及临床意义

目的测定肺癌患者血清内皮抑素水平，探讨其在肺癌的诊断价值及其与化疗的关系。方法应用酶联免疫吸附试验（ELISA法），测定44例原发性肺癌、20例肺部良陛疾病和20例正常人血清内皮抑素含量。结果（1）肺癌组血清内皮抑素水平（6．33±0．80ng／ml）高于肺部良性病变组（3．91±0．54ng／ml）和正常对照组（3．72±0．58ns／ml），差异具有显著性（P=0．000，P=0．000）。（2）肺癌患者血清内皮抑素水平与肿瘤组织类型无关（P=0．392）。（3）肺癌患者化疗后血清内皮抑素水平（6．73±0．52ng／ml）高于化疗前（6．09±0．83ng／ml），差异有统计学意义（P=0．037）。结论肺癌患者血清内皮抑素表达水平明显增高，可作为预测肺癌恶性度和治疗反应的评价指标。

Significance of serum endostatin levels in patients with lung cancer

Objective To investigate the value of serum level of endostatin in the diagnosis of lung cancer. Methods Serum levels of endostatin were measured by an enzyme-linked immunosorbent assay (ELISA) in 44 patients with lung cancer, 20 patients with benign lung diseases and 20 normal persons. Results (1) The serum level of endostatin in the lung cancer patients was 6.47±0.81 ng/ml, which was significantly higher than those of the patients with benign lung diseases and of the healthy group(3.91±0.54 ng/ml and 3.72±0.58 ng/ml, respectively, both P＜0.001). (2) There was no significant difference in the serum level of endostatin among the lung cancer patients with different pathological types. (3) The serum level of endostatin in the lung cancer patients after chemotherapy was 6.73±0.52 ng/ml, which was higher than that before the chemotherapy (6.09±0.83 ng/ml, P=0.037). Conclusion Serum level of endostatin is elevated in patients with lung cancer. It may be used to evaluate the biological behavior of lung cancer.